Search Results - "Lazzaro, Antonio"
-
1
T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms
Published in International journal of molecular sciences (25-04-2023)“…Castleman disease (CD) is a rare lymphoproliferative disorder that includes various clinico-pathological subtypes. According to clinical course, CD is divided…”
Get full text
Journal Article -
2
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
Published in Journal of clinical oncology (10-06-2007)“…We performed a prospective, randomized study of single (arm A) versus double (arm B) autologous stem-cell transplantation (ASCT) for younger patients with…”
Get full text
Journal Article -
3
Characteristics and outcomes of five patients with COVID‐19 and hematological malignancies
Published in Clinical case reports (01-06-2021)“…Patients with hematological cancer are at major risk of developing infectious complication. The prevention and treatment of COVID‐19 in these patients is…”
Get full text
Journal Article -
4
Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience
Published in Journal of clinical oncology (20-01-2005)“…Hepatitis C virus (HCV) is endemic in some areas of Northwestern Europe and the United States. HCV has been shown to play a role in the development of both…”
Get full text
Journal Article -
5
Ultrasound-guided central venous catheterization in cancer patients improves the success rate of cannulation and reduces mechanical complications: a prospective observational study of 1,978 consecutive catheterizations
Published in World journal of surgical oncology (19-10-2010)“…A central venous catheter (CVC) currently represents the most frequently adopted intravenous line for patients undergoing infusional chemotherapy and/or…”
Get full text
Journal Article -
6
Visualization of Fingermarks Deposits on Untreated Thermal Paper Exploiting the Near Infrared Luminescence
Published in Journal of forensic sciences (01-01-2020)“…Thermal paper is widely used as a print medium for different applications but it constitutes a tricky substrate for fingermark visualization. An earlier work…”
Get full text
Journal Article -
7
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study
Published in Haematologica (Roma) (01-03-2008)“…1 Dipartimento di Oncologia ed Ematologia Università di Modena Centro Oncologico Modenese, Policlinico Modena 2 Dipartimento di Oncologia, Ospedale Santo…”
Get full text
Journal Article -
8
Role of image-guided fine-needle aspiration biopsy in the management of patients with splenic metastasis
Published in World journal of surgical oncology (02-02-2007)“…Splenic metastases are very rare and are mostly diagnosed at the terminal phase of the disease or at the time of autopsy. The cytohistological diagnosis, when…”
Get full text
Journal Article -
9
Prognostic relevance of serum β2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study
Published in Haematologica (Roma) (01-11-2007)“…Background and Objectives Although serum β2 microglobulin (β2 M) is an easy parameter to measure, and over-expressed in a large number of lymphoproliferative…”
Get full text
Journal Article -
10
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
Published in The lancet oncology (01-07-2018)“…Twice a week carfilzomib at 27 mg/m2 is approved for treatment of relapsed or refractory multiple myeloma. Phase 1/2 CHAMPION-1, the first study exploring…”
Get full text
Journal Article -
11
OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses
Published in Blood (23-11-2021)“…Background: Most pts with MM are older (median age at diagnosis: 69 y), have comorbidities (Engelhardt, et al. Haematologica. 2017;102:910), and often relapse…”
Get full text
Journal Article -
12
Radial Neck Fractures in Children: Results When Open Reduction Is Indicated
Published in Journal of pediatric orthopaedics (01-12-2014)“…BACKGROUND:Radial neck fractures in children are rare, representing 5% of all elbow pediatric fractures. Most are minimally displaced or nondisplaced. Severely…”
Get full text
Journal Article -
13
Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
Published in Blood (02-11-2023)“…Background/Introduction: Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases resulting in rapid release…”
Get full text
Journal Article -
14
Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab
Published in Clinical rheumatology (01-07-2015)“…Muckle-Wells syndrome (MWS) is a rare hereditary autoinflammatory disorder characterized by recurrent urticaria-like skin rashes, arthralgias, conjunctivitis,…”
Get full text
Journal Article -
15
Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines
Published in Blood (29-11-2018)“…Introduction: The phase 3 A.R.R.O.W. study (NCT02412878) has shown a favorable benefit-risk profile of once-weekly carfilzomib (K) at 70 mg/m2 over…”
Get full text
Journal Article -
16
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
Published in The Lancet. Haematology (01-02-2022)“…Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus dexamethasone showed clinical activity and manageable safety in the phase 2…”
Get full text
Journal Article -
17
-
18
Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W
Published in Journal of clinical oncology (20-05-2018)“…Abstract only…”
Get full text
Journal Article -
19
Bortezomib‐ and thalidomide‐induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study
Published in American journal of hematology (01-12-2014)“…A subanalysis of the GIMEMA‐MMY‐3006 trial was performed to characterize treatment‐emergent peripheral neuropathy (PN) in patients randomized to…”
Get full text
Journal Article -
20
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
Published in European journal of haematology (06-10-2024)“…Isatuximab, a novel anti-CD38 monoclonal antibody, is approved in combination with carfilzomib and dexamethasone (Isa-Kd) in relapsed/refractory multiple…”
Get full text
Journal Article